TY - JOUR
T1 - Patient-reported health preferences of anticoagulant-related outcomes
AU - Wang, Ye
AU - Xie, Feng
AU - Kong, Ming Chai
AU - Lee, Lai Heng
AU - Ng, Heng Joo
AU - Ko, Yu
N1 - Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/10/24
Y1 - 2015/10/24
N2 - Strokes can have a catastrophic impact on patients’ health-related quality of life (HRQoL). In addition to warfarin, two novel oral anticoagulants, i.e., dabigatran and rivaroxaban, have been approved to prevent strokes. This study aimed to use direct measures to elicit patient-reported utilities (i.e., preferences) for anticoagulant-related outcomes. A cross-sectional survey was administered to 100 patients taking warfarin in an anticoagulation clinic. Utilities for six long-term and four short-term anticoagulant-related health states were elicited by the visual analogue scale (VAS) and standard gamble (SG) methods. Health states with the highest SG-derived mean utility values were “well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 ± 0.17), and “well on dabigatran” (0.83 ± 0.18). Approximately half of the patients considered major ischemic stroke (−1.57 ± 6.77) and intracranial hemorrhage (−1.99 ± 6.98) to be worse than death. The percentages of patients who considered a particular health state worse than death ranged from 0 to 55 % among various health states assessed. The VAS had similar findings. Good logical consistency was observed in both VAS- and SG-derived utility values. Ischemic stroke and intracranial hemorrhage had a significant impact on patients’ HRQoL. Greater variation in patients’ preferences was observed for more severely impaired health states, indicating the need for individualized medical decision-making. In this study, both long-term and short-term health states were included in the utility assessment. The findings of this study can be used in cost-utility analysis of future anticoagulation therapies.
AB - Strokes can have a catastrophic impact on patients’ health-related quality of life (HRQoL). In addition to warfarin, two novel oral anticoagulants, i.e., dabigatran and rivaroxaban, have been approved to prevent strokes. This study aimed to use direct measures to elicit patient-reported utilities (i.e., preferences) for anticoagulant-related outcomes. A cross-sectional survey was administered to 100 patients taking warfarin in an anticoagulation clinic. Utilities for six long-term and four short-term anticoagulant-related health states were elicited by the visual analogue scale (VAS) and standard gamble (SG) methods. Health states with the highest SG-derived mean utility values were “well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 ± 0.17), and “well on dabigatran” (0.83 ± 0.18). Approximately half of the patients considered major ischemic stroke (−1.57 ± 6.77) and intracranial hemorrhage (−1.99 ± 6.98) to be worse than death. The percentages of patients who considered a particular health state worse than death ranged from 0 to 55 % among various health states assessed. The VAS had similar findings. Good logical consistency was observed in both VAS- and SG-derived utility values. Ischemic stroke and intracranial hemorrhage had a significant impact on patients’ HRQoL. Greater variation in patients’ preferences was observed for more severely impaired health states, indicating the need for individualized medical decision-making. In this study, both long-term and short-term health states were included in the utility assessment. The findings of this study can be used in cost-utility analysis of future anticoagulation therapies.
KW - Anticoagulant
KW - Preference
KW - Stroke
KW - Utility
KW - Warfarin
UR - http://www.scopus.com/inward/record.url?scp=84940440115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940440115&partnerID=8YFLogxK
U2 - 10.1007/s11239-015-1191-9
DO - 10.1007/s11239-015-1191-9
M3 - Article
C2 - 25875937
AN - SCOPUS:84940440115
SN - 0929-5305
VL - 40
SP - 268
EP - 273
JO - Journal of Thrombosis and Thrombolysis
JF - Journal of Thrombosis and Thrombolysis
IS - 3
ER -